Mark McKenna - Prometheus Biosciences CEO Pres
Insider
Mark McKenna is CEO Pres of Prometheus Biosciences
| Age | 43 |
| Phone | 858 684 1300 |
| Web | https://www.prometheusbiosciences.com |
Mark McKenna Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark McKenna against Prometheus Biosciences stock is an integral part of due diligence when investing in Prometheus Biosciences. Mark McKenna insider activity provides valuable insight into whether Prometheus Biosciences is net buyers or sellers over its current business cycle. Note, Prometheus Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Prometheus Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark McKenna over a year ago Disposition of 178098 shares by Mark McKenna of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 122528 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 25000 shares of Prometheus Biosciences subject to Rule 16b-3 | ||
Mark McKenna over a year ago Exercise or conversion by Mark McKenna of 700 shares of Prometheus Biosciences subject to Rule 16b-3 |
Prometheus Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.2006) % which means that it has lost $0.2006 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.333) %, meaning that it created substantial loss on money invested by shareholders. Prometheus Biosciences' management efficiency ratios could be used to measure how well Prometheus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Prometheus Biosciences currently holds 14.76 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Prometheus Biosciences has a current ratio of 13.05, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Prometheus Biosciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Dr MBA | Blueprint Medicines Corp | 55 | |
| Michael MBA | Arcellx | N/A | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Marianne Romeo | Roivant Sciences | 56 | |
| Rakhi Kumar | Roivant Sciences | 45 | |
| Hal MD | Pliant Therapeutics | N/A | |
| Gloria Lin | Krystal Biotech | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Timothy Rolph | Akero Therapeutics | 71 | |
| Robert Waltermire | Madrigal Pharmaceuticals | 61 | |
| Matthew Gline | Roivant Sciences | 41 | |
| David Tice | Arcellx | 53 | |
| Ryan Martins | 89bio Inc | 47 | |
| Christopher MD | Arcellx | 45 | |
| Justin Klee | Amylyx Pharmaceuticals | 34 | |
| William JD | Akero Therapeutics | 51 | |
| Melissa Abel | 89bio Inc | N/A | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Margaret MBA | Amylyx Pharmaceuticals | 59 | |
| Shauna Horvath | Amylyx Pharmaceuticals | N/A | |
| Quoc LeNguyen | 89bio Inc | 57 | |
Management Performance
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 |
Prometheus Biosciences Leadership Team
Elected by the shareholders, the Prometheus Biosciences' board of directors comprises two types of representatives: Prometheus Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Prometheus. The board's role is to monitor Prometheus Biosciences' management team and ensure that shareholders' interests are well served. Prometheus Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Prometheus Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Allison MD, Chief Officer | ||
| Noel Kurdi, VP Communications | ||
| Timothy Esq, G Sec | ||
| Chris Doughty, Chief Officer | ||
| Mark McKenna, CEO Pres | ||
| Nori Ebersole, Chief Officer | ||
| Olivier Laurent, Chief RD | ||
| MBA MBA, Chief Officer | ||
| Mark Stenhouse, Chief Officer |
Prometheus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Prometheus Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Operating Margin | (40.65) % | |||
| Current Valuation | 4.39 B | |||
| Shares Outstanding | 47.81 M | |||
| Shares Owned By Insiders | 16.61 % | |||
| Shares Owned By Institutions | 81.01 % | |||
| Number Of Shares Shorted | 4.68 M | |||
| Price To Earning | (5.66) X | |||
| Price To Book | 19.88 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |